Thalidomide in the treatment of multiple myeloma

Expert Review of Anticancer Therapy

Volumn 1, Issue 1, 2001, Pages 20-28

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; bFGF; Cancer; Multiple myeoma; Thalidomide; Treatment; VEGF

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRESCRIPTION; RASH; SEDATION; SIDE EFFECT; STEM CELL TRANSPLANTATION; TERATOGENICITY;

EID: 0035557940     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.1.20     Document Type: Article

References (79)

1. Multiple myeloma
2. Cancer Statistics
3. 'Benign' monoclonal gammopathy after 20 to 35 years of follow-up
4. Staging, kinetics and prognosis of multiple myeloma
5. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
6. Intensive treatment strategies in myeloma
7. The treatment of multiple myeloma
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479
9. The role of autologous hematopoietic stem cell transplantation in multiple myeloma
10. Biology and therapy of multiple myeloma in 1996
11. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation
12. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
13. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial
14. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol
15. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
16. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
17. Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM)
18. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
19. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: Phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486
20. Interferon in the treatment of multiple myeloma
21. Maintenance treatment with recombinant interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy
22. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group
23. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study
24. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study
25. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group
26. Interferon-α for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
27. The role of bisphosphonates in multiple myeloma
28. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
29. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
30. Bone marrow angiogenesis and progression in multiple myeloma
31. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
32. Prognostic value of bone marrow angiogenesis in multiple myeloma
33. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
34. Thalidomide is an inhibitor of angiogenesis
35. Antitumor activity of thalidomide in refractory multiple myeloma
36. A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma
37. Thalidomide and congenital abnormalities
38. Thalidomide and congenital abnormalities
39. Was tumour necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s?
40. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
41. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
42. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer
43. Clinical experience with thalidomide in patients with cancer
44. Pharmacology of thalidomide
45. A Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas
46. Thalidomide in multiple myeloma
47. Thalidomide-a revival story
48. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
49. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs
50. The effect of thalidomide on experimental tumors and metastases
51. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
52. A Phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies
53. Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM)
54. Bone marrow (BM) angiogenesis in multiple myeloma (MM): Effect of therapy and prognostic value
55. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
56. Binding of thalidomide to α1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production
57. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset
58. The immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
59. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
60. STEPS: A comprehensive program for controlling and monitoring access to thalidomide
61. Thalidomide (T) in the management of multiple myeloma (MM): The Arkansas Experience in > 300 patients (Pts) with single agent (SA) and combination chemotherapy (CT)
62. Long term follow up of 169 patients receiving a Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM)
63. Thalidomide in the treatment of relapsed and refractory myeloma
64. Thalidomide in the treatment of relapsed multiple myeloma
65. Thalidomide in patients with advanced myeloma: Survival prognostic factors
66. Thalidomide alone or with dexamethasone for multiple myeloma
67. Durable response to thalidomide in relapsed/refractory multiple myeloma (MM)
68. Efficacy of low dose thalidomide (T) in multiple myeloma
69. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
70. Therapy with thalidomide in refractory multiple myeloma - The revival of an old drug
71. Clinical and biological activity of thalidomide (THAL) in multiple myeloma (MM)
72. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters
73. Thalidomide with dexamethasone for resistant multiple myeloma
74. Single course DT PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM)
75. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma
76. Non-myelosuppressive therapy with BLT-D (Biaxin®, low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma
77. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
78. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM)
79. The current status of thalidomide in the treatment of cancer